بررسي اثر عصاره تركيبي شويد(Anethum) بر روي ليپيدها و ليپوپروتئين هاي پلاسما در رت هاي سالم و ديابتي

The effects of Anethum on plasma lipid and lipoprotein in normal and diabetic rats fed high fat diets

Background and aim: Hypelipidemia is considered to be a major risk factor in the progression of coronary atherosclerosis and is associated with increase in the incidence of cardiac events. Anethum is used as a lipid lowering in Iran. The present study investigated the hypolipidemic effects of Anethum in normal and streptozocin- induced diabetic rats fed high fat diet. Methods: Animals were treated once with streptozocin (60 mg/kg, i.p) and two days later normal and diabetic rats were under a special high fat diet. One week after initiation of the special high fat diet, animals were treated daily by oral administration of Anethum. All treatments continued for three weeks after which blood samples were collected -following an overnight fast- from retro-orbital sinus and the serum was separated. Then total triglyceride, total cholesterol and HDL-C in each serum sample were determined enzymatically using commercial kits and serum LDL-C levels were derived using the Friedewald formula. Results: In both normal and diabetic rats fed high fat diet blood levels of glucose, lipids and LDL-C were increased as compared with control normal rats. Furthermore, in normal rats fed high fat diet, Anethum significantly decreased triglyceride (P<0.01) and LDL-C (P<0.01) and increased HDL-C (P<0.05), but could not affect blood glucose level. Anethum had not antilipidemic effect on diabetic rats fed high fat diet while Anethum increased blood glucose level. In addition, Anethum decreased body weight in normal and diabetic rats. Conclusion: The results of this study show that Anethum has a strong antilipidemic effect in normal rats fed high fat diet, but is not an effective drug for lipid lowering in Streptozocin- induced diabetic rats fed high fat diet. Thus, precautious consumption of this drug must be taken in consideration for diabetic patients.